AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$LUNG

Rose Geoffrey Beran sold $12K of LUNG

Rose Geoffrey Beran (CHIEF COMMERCIAL OFFICER) sold 8,023 shares of Pulmonx Corp (LUNG) at $1.54 across 4 trades on 2026-06-01.

Original reporting
SEC EDGAR · Rose Geoffrey Beran
Published Jun 3, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
high confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The modest sale is unlikely to move the stock significantly but adds a data point for monitoring insider activity.

02

Market read

Small insider sell; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post-filing today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$LUNGBearishHigh confidence
Context

Chief Commercial Officer Rose Geoffrey Beran sold 8,023 shares for $12,355 total on June 1, 2026.

Expected impact

likely modest pressure as market prices in the insider sell

Evidence & confidence

Sale size is $12k against 457,711 shares held; investors may view it as a neutral to slightly negative signal.

Market effects

Sector

minimal impact on medical device sector

Regional

none

Global

none

Counterpoint

What could challenge this read

Insider may be diversifying personal portfolio; sale does not reflect company fundamentals.

Key entities

  • Company
    Pulmonx Corp

    Medical device company listed on Nasdaq under ticker LUNG.

  • Executive
    Rose Geoffrey Beran

    Chief Commercial Officer of Pulmonx Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LUNG insider trading history →

Related articles

OCT 27
$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

finance.yahoo.com3 min
OCT 27
$LUNGMed

Pulmonx Reports Third Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi

SEC EDGAR 8-K2 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min